Trinity Biotech (TRIB) PT Lowered to $20 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Trinity Biotech (TRIB) PT Lowered to $20 at Roth Capital
July 28, 2015 9:29 AM EDT
DUBLIN, July 28, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2015.
Quarter 2 Results                                                                                          Total revenues for Q2, 2015 were $24.3m compared to $26.0m in Q2, 2014. However, when the impact of foreign exchange movements, due to the strength of the US dollar against a range of other currencies, is removed, revenues would have been $25.4m this quarter, thus representing a decrease of 2%.Â
Point-of-Care revenues for Q2, 2015 were $3.4m, which represents a decrease of... More
